Hemrajani Rekha — SEC Form 4 filings
SEC reporting owner CIK 1771213. 14 Form 4 filings on record with FilingPulse; latest filed 2026-06-22.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-06-13 to 2026-06-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 33,000 shares, $100,404 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 10,684 shares, $22,378 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: purchase of 3,000 shares @ $18.00 ($54,000) in BioAge Labs, Inc., filed 2025-03-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | Director | 4 | 1 leg · 3,000 sh · $54,000 | — | 4 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | Director | 4 | 1 leg · 30,000 sh · $46,404 | — | 3 |
| MAXCYTE, INC. (MXCT) | Director | 4 | — | 1 leg · 10,684 sh · $22,378 | 6 |
| LB PHARMACEUTICALS INC (LBRX) | Director | 2 | — | — | 2 |
Form 4 filings — Hemrajani Rekha
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-22 | 4 | MAXCYTE, INC. (MXCT) | Grant/award (A): 30,421 @ $0 · Grant/award (A): 49,579 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | BioAge Labs, Inc. (BIOA) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | LB PHARMACEUTICALS INC (LBRX) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | ALX ONCOLOGY HOLDINGS INC (ALXO) | Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | LB PHARMACEUTICALS INC (LBRX) | Grant/award (A): 22,449 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | MAXCYTE, INC. (MXCT) | Sale (S): 10,684 @ $2.09 | EDGAR |
| 2025-06-23 | 4 | MAXCYTE, INC. (MXCT) | Grant/award (A): 29,210 @ $0 · Grant/award (A): 50,790 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | BioAge Labs, Inc. (BIOA) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4/A | BioAge Labs, Inc. (BIOA) | Purchase (P): 3,000 @ $18 | EDGAR |
| 2025-01-23 | 4 | ALX ONCOLOGY HOLDINGS INC (ALXO) | Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2024-12-04 | 4 | ALX ONCOLOGY HOLDINGS INC (ALXO) | Purchase (P): 30,000 @ $1.55 | EDGAR |
| 2024-09-27 | 4 | BioAge Labs, Inc. (BIOA) | Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 28,497 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | ALX ONCOLOGY HOLDINGS INC (ALXO) | Grant/award (A): 20,200 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | MAXCYTE, INC. (MXCT) | Grant/award (A): 21,367 @ $0 · Grant/award (A): 40,701 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1771213 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →